Gut Bacteria: A Shield Against Deadly Pneumonia After Influenza
A groundbreaking study has revealed a fascinating connection between gut bacteria and the body's defense against severe complications following influenza. Researchers from the Institute for Biomedical Sciences at Georgia State University have discovered that certain gut bacteria can significantly reduce the risk of secondary bacterial pneumonia in mice after they recover from the flu.
The study, published in the journal Science Immunology, delves into the role of intestinal bacteria in shaping an individual's vulnerability to secondary bacterial infections. It specifically focuses on segmented filamentous bacteria (SFB), which are commonly found in the intestines of mammals. The research aimed to understand whether SFB could influence the susceptibility of mice to common respiratory bacterial pathogens like Streptococcus pneumoniae, Haemophilus influenzae, or Staphylococcus aureus following an influenza A virus infection.
The findings were remarkable. SFB provided substantial protection against these highly lethal infections. This discovery is crucial because many deaths during influenza pandemics are caused by secondary bacterial infections. Therefore, the composition of an individual's gut microbiota might play a critical role in determining who survives such public health crises.
The protective mechanism involves specialized immune cells called alveolar macrophages, which are known to become dysfunctional after influenza viral infection. SFB, residing on the outer surface of the intestine, triggers an epigenetic reprogramming in alveolar macrophages, enabling them to resist the influenza virus's harmful effects and maintain their ability to combat respiratory bacterial pathogens.
Vu Ngo, the lead author and research assistant professor at the Institute for Biomedical Sciences, highlighted the significance of this finding: "The intestine is typically colonized by thousands of different bacterial species, yet adding just one more species can dramatically alter the way lung macrophages respond to pathogens."
This study opens up exciting possibilities for developing novel pharmacological approaches to combat respiratory infections. Andrew T. Gewirtz, the senior author, expressed optimism about harnessing the mechanism by which SFB reprograms alveolar macrophages, potentially leading to new treatments for a wide range of respiratory infections.
The research team included Carolin M. Lieber, Hirohito Abo, Michal Kuczma, Jun Zou, and Richard K. Plemper, all from the Institute for Biomedical Sciences. The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), further emphasizing the importance of this discovery.
This study not only sheds light on the intricate relationship between gut bacteria and immune response but also highlights the potential for targeted interventions to improve outcomes during influenza and other respiratory infections.
